• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Halozyme Therapeutics Inc.

    8/14/24 4:08:38 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HALO alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001528185
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    HALOZYME THERAPEUTICS, INC.
    SEC File Number
    001-32335
    Address of Issuer
    12390 El Camino Real
    San Diego
    CALIFORNIA
    92130
    Phone
    (858) 794-8889
    Name of Person for Whose Account the Securities are To Be Sold
    HELEN TORLEY
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    10000572472.0012667828008/14/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON08/14/2024Stock Option ExerciseISSUERCheckbox not checked1000008/14/2024Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    HELEN TORLEY
    12390 El Camino Real
    San Diego � CA � 92130
    Common08/13/202410000562496.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    08/14/2024
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/22/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Helen Imelda Torley

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $HALO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HALO

    DatePrice TargetRatingAnalyst
    12/4/2025$56.00Neutral → Sell
    Goldman
    10/14/2025$70.00Underperform → Market Perform
    Leerink Partners
    8/6/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    7/10/2025$55.00Neutral
    Goldman
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $HALO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

    SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading. Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/624893800?pwd=q3lpEa6F A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a bioph

    2/10/26 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

    Updates Preliminary Unaudited 2025 Estimates:- Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1- Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30%2 - Increases Royalty Revenue to $1,130 - $1,170 million, YoY Growth of 30% to 35%2 - Increases Adjusted EBITDA to $1,125 - $1,205 million3,4- Increases non-GAAP Diluted EPS to $7.75 - $8.253,4 Expands Drug Delivery Opportunity with Acquisition of Surf Bio and its Hyperconcentration Technology Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- Halozyme T

    1/28/26 6:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

    SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I1205969. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made ava

    1/20/26 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Halozyme Therapeutics downgraded by Goldman with a new price target

    Goldman downgraded Halozyme Therapeutics from Neutral to Sell and set a new price target of $56.00

    12/4/25 8:27:01 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Halozyme Therapeutics from Underperform to Market Perform and set a new price target of $70.00

    10/14/25 1:19:46 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Halozyme Therapeutics from Equal-Weight to Overweight and set a new price target of $75.00

    8/6/25 7:53:02 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $HALO
    SEC Filings

    View All

    SEC Form 4 filed by SVP, CHIEF OPERATING OFFICER Caudill Cortney

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    2/11/26 9:21:33 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by SVP, CHIEF LEGAL OFFICER Snyder Mark Howard

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    2/11/26 9:20:59 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    2/11/26 9:20:34 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    1/28/26 6:40:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    12/9/25 4:45:01 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    12/8/25 5:20:13 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Financials

    Live finance-specific insights

    View All

    Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

    SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading. Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/624893800?pwd=q3lpEa6F A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a bioph

    2/10/26 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

    Updates Preliminary Unaudited 2025 Estimates:- Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1- Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30%2 - Increases Royalty Revenue to $1,130 - $1,170 million, YoY Growth of 30% to 35%2 - Increases Adjusted EBITDA to $1,125 - $1,205 million3,4- Increases non-GAAP Diluted EPS to $7.75 - $8.253,4 Expands Drug Delivery Opportunity with Acquisition of Surf Bio and its Hyperconcentration Technology Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- Halozyme T

    1/28/26 6:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

    SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I1205969. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made ava

    1/20/26 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.

    SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    11/12/24 9:36:57 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Halozyme Therapeutics Inc.

    SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    10/17/24 9:36:19 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)

    SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    2/13/24 5:06:13 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Leadership Updates

    Live Leadership Updates

    View All

    Jim Lang Elected to Halozyme's Board of Directors

    SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics. "Jim brings extensive experience in building and scaling innovative healthcare businesses, and we are delighted to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His strategic insight and proven ability to drive growth, including through M&A, will be a tremendous asset as we deliver on our growth strategy and create meaningful new value for our

    12/8/25 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

    9/4/24 8:00:00 AM ET
    $AVTX
    $DRRX
    $HALO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medicinal Chemicals and Botanical Products

    Mahesh Krishnan Elected to Halozyme's Board of Directors

    SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.

    4/25/24 4:45:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care